# US 2020/0390804 A1 · Nanoclays for the control of melanoma cell proliferation and cell viability

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390804 A1
- Document ID: US20200390804A1
- Status: Published application
- Kind: A1
- Application number: 16/439,126
- Filed: 2019-06-12
- Published: 2020-12-17
- Earliest claimed: 2019-06-12
- Assignees: King Fahd University of Petroleum and Minerals
- Applicants: King Fahd University of Petroleum and Minerals
- Inventors: Sahel N. ABDULJAUWAD; Habib-ur-Rehman AHMED
- Web page: https://patentgrep.com/patent/US20200390804A1

## CPC

- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/404: Indoles, e.g. pindolol
- A61P 17/00: Drugs for dermatological disorders
- A61P 35/00: Antineoplastic agents
- C12N 5/0625: {Epidermal cells, skin cells; Cells of the oral mucosa}
- C12N 5/0693: {Tumour cells; Cancer cells}
- A61K 9/10: Dispersions; Emulsions
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention pertains to a method for reducing proliferation or viability of melanoma cells by contacting the cells with nanoclay. It also involves pharmaceutical composition containing nanoclay for treatment of melanoma.

## Claims

### Claim at position 1

1: A method for reducing melanoma cell growth viability, comprising:
mixing the melanoma cells with a treatment composition consisting essentially of at least one nanoclay selected from the group consisting of a palygorskite and a montmorillonite as an active ingredient, to form a cell growth mixture, then
incubating the cell growth mixture for from 3 to 5 days;
wherein during the mixing the melanoma cells are present in a growth medium consisting essentially of water, amino acids and glucose,
wherein the treatment composition contains the active ingredient in an amount of from 1 to 25 μg/ml,
wherein after the incubating, the melanoma cell growth viability of the melanoma cells is reduced by at least 50% in comparison to the melanoma cell growth viability of a control growth mixture that is mixed with a control composition that is the same as the treatment composition but does not contain the active ingredient.

### Claim 2 (depends on 1)

The method of claim 1, wherein said treatment composition contains the active ingredient in a concentration ranging from about 2 to 20 μg of the per cc or per gram of the treatment composition.

### Claim 3 (depends on 1)

The method of claim 1, wherein said treatment composition contains the active ingredient in a concentration ranging from about 2 to 10 μg of the nanoclay per cc of per gram of the treatment composition.

### Claim at position 4 (depends on 1)

4: The method of claim 1, wherein the at least one nanoclay consists essentially of palygorskite.

### Claim 5 (depends on 1)

The method of claim 1, wherein the at least one nanoclay consists of palygorskite which has the formula (Mg,Al)2Si4O10(OH).4H2O.

### Claim at position 6 (depends on 1)

6: The method of claim 1, wherein the at least one nanoclay consists essentially of a montmorillonite.

### Claim at position 7 (depends on 1)

7: The method of claim 1, wherein the at least one nanoclay comprises a Na-rich montmorillonite having the formula (Na,Ca)0.33 (Al, Mg)2(Si4O10).

### Claim 8 (depends on 1)

The method of claim 1, wherein the at least one nanoclay comprises a mixture of a palygorskite which has the formula (Mg,Al)2Si4O10(OH).4H2O and a Na-rich montmorillonite having the formula (Na, Ca)0.33(Al,Mg2(Si4O10).

### Claim at position 9

9: A method for treating a subject having melanoma or another skin cancer comprising:
administering a composition consisting essentially of at least one nanoclay selected from the group consisting of a palygorskite and a montmorillonite as an active ingredient to the subject, and, optionally, at least one inactive carrier or excipient.

### Claim 10 (depends on 9)

The method of claim 9, wherein said composition contains the at least one nanoclay in a concentration ranging from about 1 to 200 μg of the nanoclay per cc or per gram of the composition.

### Claim 11 (depends on 9)

The method of claim 9, wherein said composition contains the at least one nanoclay in a concentration ranging from about 2 to 20 μg of the nanoclay per cc of per gram of the composition.

### Claim at position 12 (depends on 9)

12: The method of claim 9, wherein the at least one nanoclay consists essentially of palygorskite.

### Claim 13 (depends on 9)

The method of claim 9, wherein the at least one nanoclay consists of palygorskite which has the formula (Mg, Al)2Si4O10(OH).4H2O.

### Claim at position 14 (depends on 9)

14: The method of claim 9, wherein the at least one nanoclay consists essentially of a montmorillonite.

### Claim at position 15 (depends on 9)

15: The method of claim 9, wherein the at least one nanoclay comprises a Na-rich montmorillonite having the formula (Na, Ca)0.33(Al, Mg)2(Si4O10).

### Claim 16 (depends on 9)

The method of claim 9, wherein the at least one nanoclay comprises a mixture of a palygorskite which has the formula (Mg, Al)2Si4O10(OH).4H2O and a Na-rich montmorillonite having the formula (Na, Ca)0.33(Al, Mg)2(Si4O10).

### Claim 17 (depends on 9)

The method of claim 9, wherein the at least one nanoclay is administered topically.

### Claim 18 (depends on 9)

The method of claim 9, wherein at least one nanoclay is administered intradermally or subcutaneously.

### Claim 19 (depends on 1)

The method of claim 1, wherein the at least one nanoclay is administered into or around a dermal site after removal of melanoma cells.

### Claim 20 (depends on 1)

The method of claim 1, wherein the subject has been administered at least one other anti-cancer therapy.
